NCT04942067 2023-10-25APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple MyelomaAscentage Pharma Group Inc.Phase 1/2 Unknown108 enrolled
NCT04674514 2023-03-07APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple MyelomaAscentage Pharma Group Inc.Phase 1/2 Unknown48 enrolled